Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
BOLD
$1.17
$
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Next Earnings
2026-02-25
Beta
-0.1209024
Average Volume
Market Cap
Last Dividend
CIK
0001782303
ISIN
US10170A1007
CUSIP
10170A100
CEO
Zachary Hornby
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
64
IPO Date
2016-07-20
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why | Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | Zacks Investment Research | 2026-02-13 13:01:08 |
| Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. | GlobeNewsWire | 2026-02-05 07:00:00 |
| Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway | BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second half of 2028 SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its novel Kinesin oral degrader program, BBI-940. The Company also provided updates on the POTENTIATE clinical trial of BBI-355 and BBI-825 and its capital position. | GlobeNewsWire | 2026-01-20 07:00:00 |
| BUBBA® UNVEILS A BOLD, NEW BRAND IDENTITY AND NEXT-GEN WATER BOTTLE DESIGNS, TURNING EVERYDAY HYDRATION INTO PERSONAL EXPRESSION | It's Not About the Water, It's About the Drip. bubba®'s New Look, Fashion-forward Finishes, And Bold Colorways, Transform Hydration into a Statement Piece ATLANTA, Jan. 14, 2026 /PRNewswire/ -- Today, bubba® , part of Newell Brands' global portfolio and an emerging leader in oversized, high-performance water bottles, announces a bold evolution of its brand identity alongside the launch of a new generation of reuseable water bottle designs. | PRNewsWire | 2026-01-14 07:00:00 |
| 21shares launches BOLD ETP combining bitcoin and gold in a single regulated product | Approved by Archax 12/01/2026 Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. | GlobeNewsWire | 2026-01-13 04:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-01-26 | 2026-01-26 | View Filing |
| 4 | 2026-01-26 | 2026-01-26 | View Filing |
| 4 | 2026-01-26 | 2026-01-26 | View Filing |
| 4 | 2026-01-26 | 2026-01-26 | View Filing |
| 4 | 2026-01-26 | 2026-01-26 | View Filing |
| SC 13G | 2025-12-04 | 2025-12-04 | View Filing |
| 10-Q | 2025-11-05 | 2025-11-05 | View Filing |
| 8-K | 2025-11-05 | 2025-11-05 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-08-05 | 2025-08-05 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-05-23 | 2025-05-23 | View Filing |
| 10-Q | 2025-05-09 | 2025-05-09 | View Filing |
| 8-K | 2025-05-09 | 2025-05-09 | View Filing |
| ARS | 2025-04-29 | 2025-04-29 | View Filing |
| DEFA14A | 2025-04-29 | 2025-04-29 | View Filing |
| DEF 14A | 2025-04-29 | 2025-04-29 | View Filing |
| EFFECT | 2025-04-11 | 2025-04-11 | View Filing |
| 8-K | 2025-04-01 | 2025-04-01 | View Filing |
| S-3 | 2025-04-01 | 2025-04-01 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 3 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 8-K | 2024-12-12 | 2024-12-12 | View Filing |
| 10-Q | 2024-11-07 | 2024-11-07 | View Filing |
| 8-K | 2024-11-07 | 2024-11-07 | View Filing |
| SC 13D | 2024-10-29 | 2024-10-29 | View Filing |
| 3 | 2024-10-15 | 2024-10-15 | View Filing |
| 8-K | 2024-10-15 | 2024-10-15 | View Filing |
| 4 | 2024-08-20 | 2024-08-20 | View Filing |
| 4 | 2024-08-20 | 2024-08-20 | View Filing |
| 4 | 2024-08-20 | 2024-08-20 | View Filing |
| 4 | 2024-08-20 | 2024-08-20 | View Filing |
| 4 | 2024-08-20 | 2024-08-20 | View Filing |
| 4 | 2024-08-20 | 2024-08-20 | View Filing |
| 8-K | 2024-08-20 | 2024-08-20 | View Filing |
| 8-K | 2024-08-12 | 2024-08-12 | View Filing |
| 10-Q | 2024-08-12 | 2024-08-12 | View Filing |
| 4 | 2024-06-20 | 2024-06-20 | View Filing |
| 10-Q | 2024-05-13 | 2024-05-13 | View Filing |
| 8-K | 2024-05-13 | 2024-05-13 | View Filing |
| SC 13G | 2024-04-12 | 2024-04-12 | View Filing |
| SC 13G | 2024-04-12 | 2024-04-12 | View Filing |
| SC 13G | 2024-04-10 | 2024-04-10 | View Filing |
| SC 13G | 2024-04-09 | 2024-04-09 | View Filing |
| 4 | 2024-04-04 | 2024-04-04 | View Filing |
| 4 | 2024-04-04 | 2024-04-04 | View Filing |
| 4 | 2024-04-04 | 2024-04-04 | View Filing |
| 4 | 2024-04-04 | 2024-04-04 | View Filing |
| 4 | 2024-04-04 | 2024-04-04 | View Filing |
| 4 | 2024-04-02 | 2024-04-02 | View Filing |
| 8-K | 2024-04-02 | 2024-04-02 | View Filing |
| 4 | 2024-03-29 | 2024-03-29 | View Filing |
| 4 | 2024-03-29 | 2024-03-29 | View Filing |
| 4 | 2024-03-29 | 2024-03-29 | View Filing |
| 4 | 2024-03-29 | 2024-03-29 | View Filing |
| 4 | 2024-03-29 | 2024-03-29 | View Filing |
| 4 | 2024-03-29 | 2024-03-29 | View Filing |
| 4 | 2024-03-29 | 2024-03-29 | View Filing |
| 4 | 2024-03-29 | 2024-03-29 | View Filing |
| 4 | 2024-03-29 | 2024-03-29 | View Filing |
| 4 | 2024-03-29 | 2024-03-29 | View Filing |
| 4 | 2024-03-29 | 2024-03-29 | View Filing |
| 4 | 2024-03-29 | 2024-03-29 | View Filing |
| S-8 | 2024-03-28 | 2024-03-28 | View Filing |
| 424B4 | 2024-03-28 | 2024-03-28 | View Filing |
| EFFECT | 2024-03-28 | 2024-03-28 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| 3 | 2024-03-27 | 2024-03-27 | View Filing |
| CERT | 2024-03-27 | 2024-03-27 | View Filing |
| CORRESP | 2024-03-25 | 2024-03-25 | View Filing |
| CORRESP | 2024-03-25 | 2024-03-25 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 60.58% | 0.99 | 252 | 0.09 | 0.19 | 63.34 |
| Larry Williams PercentR Strategy | 21.63% | 0.99 | 151 | 0.03 | 0.07 | 24.4 |
| Keltner Channel Strategy | 12.94% | 0.99 | 137 | 0.02 | 0.07 | 15.7 |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | x | x | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |